Search results
Showing 706 to 720 of 2182 results for guidelines
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
Vitamin D: supplement use in specific population groups (PH56)
This guideline covers vitamin D supplement use. It aims to prevent vitamin D deficiency among specific population groups including infants and children aged under 4, pregnant and breastfeeding women, particularly teenagers and young women, people over 65, people who have low or no exposure to the sun and people with dark skin.
Over the next year, our prioritisation decisions will be shaped by the government’s strategic direction for health and life sciences, and by the needs of the NHS, local systems and the people who use services.
Find individual child abuse and neglect recommendations quickly and links to full guideline.
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
Using NICE guidance in social work: scenarios for principal social workers
They can help principal social workers (PSWs) understand how to put our guidelines and quality standards into practice. Social care...
Evidence-based recommendations on the Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters.
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
Day-to-day decision making is the responsibility of NICE's executive team.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
situations and people They can help social workers understand how to put our guidelines and quality standards into practice. Social care...
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making